Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis.

@article{AbouAlfa2011SafetyAE,
  title={Safety and Efficacy of Sorafenib in Patients with Hepatocellular Carcinoma (HCC) and Child-Pugh A versus B Cirrhosis.},
  author={Ghassan K Abou-Alfa and Dino Amadori and Armando Santoro and Ari{\'e} Figer and Jacques L P De Gr{\`e}ve and Chetan Lathia and Dimitris Voliotis and Sibyl Anderson and Marius Moscovici and Sergio Ricci},
  journal={Gastrointestinal cancer research : GCR},
  year={2011},
  volume={4 2},
  pages={40-4}
}
BACKGROUND We performed a retrospective analysis of data from a phase II study evaluating sorafenib in patients with advanced hepatocellular carcinoma (HCC) to assess differences in safety and efficacy based on Child-Pugh (CP) status (A/B). METHODS Patients received sorafenib 400 mg PO bid. We analyzed safety, pharmacokinetic (PK), and efficacy data in… CONTINUE READING